ELHAM SHAKIBA¹, SETI BOROOMAND², SIMA KHERADMAND KIA³, MEHDI HEDAYATI^4,*

Oncology Research, Vol.32, No.6, pp. 1011-1019, 2024, DOI:10.32604/or.2024.049235 - 23 May 2024

Abstract This review aimed to describe the inculpation of microRNAs (miRNAs) in thyroid cancer (TC) and its subtypes, mainly medullary thyroid carcinoma (MTC), and to outline web-based tools and databases for bioinformatics analysis of miRNAs in TC. Additionally, the capacity of miRNAs to serve as therapeutic targets and biomarkers in TC management will be discussed. This review is based on a literature search of relevant articles on the role of miRNAs in TC and its subtypes, mainly MTC. Additionally, web-based tools and databases for bioinformatics analysis of miRNAs in TC were identified and described. MiRNAs can… More > Graphic Abstract

Hyeong Won Yu¹, Muhammad Afzal², Maqbool Hussain², Hyungju Kwon³, Young Joo Park⁴, June Young Choi^1,*, Kyu Eun Lee⁵

CMC-Computers, Materials & Continua, Vol.67, No.1, pp. 1241-1251, 2021, DOI:10.32604/cmc.2021.014910 - 12 January 2021

Abstract Advances in technology are enabling gene mutations in papillary thyroid carcinoma (PTC) to be analyzed and clinical outcomes, such as recurrence, to be predicted. To date, the most common genetic mutation in PTC is in BRAF kinase (BRAF). However, whether mutations in other genes coincide with those in BRAF remains to be clarified. The aim of this study was to find mutations in other genes that co-exist with mutated BRAF, and to analyze their frequency and clinical relevance in PTC. Clinical and genetic data were collected from 213 PTC patients with a total of 36,572… More >

Fengyun Hao^*1, Qingli Zhu^†, Lingwei Lu^†, Shukai Sun^‡, Yichuan Huang^§, Jinna Zhang^¶, Zhaohui Liu^†#, Yuanqing Miao^**, Xuelong Jiao^††, Dong Chen^††1

Oncology Research, Vol.28, No.4, pp. 345-355, 2020, DOI:10.3727/096504020X15834065061807

Abstract Anaplastic thyroid carcinoma (ATC) is resistant to standard therapies and has no effective treatment. Eukaryotic translation initiation factor 5A2 (EIF5A2) has shown to be upregulated in many malignant tumors and proposed to be a critical gene involved in tumor metastasis. In this study, we aimed to investigate the expression status of EIF5A2 in human ATC tissues and to study the role and mechanisms of EIF5A2 in ATC tumorigenesis in vitro and in vivo. Expression of EIF5A2 protein was analyzed in paraffin-embedded human ATC tissues and adjacent nontumorous tissues (ANCT) (n = 24) by immunochemistry. Expressions… More >

Fang Chen^*, Dongqiang Yang^†, Yuhua Ru^‡, Shan Cao^*, Aishe Gao^*

Oncology Research, Vol.27, No.6, pp. 691-701, 2019, DOI:10.3727/096504018X15426763753594

Abstract Escalating evidence suggests that microRNA-101 (miR-101) is implicated in the development and progression of various cancers, including papillary thyroid carcinoma (PTC). However, the biological function and molecular mechanisms of miR-101 in PTC are still unclear. In this study, we demonstrated that miR-101 expression was significantly decreased in PTC tissues and cell lines. Clinically, a low level of miR-101 was positively associated with advanced histological stages and lymph node and distant metastases. The expression of CXCL12 was negatively correlated with miR-101 level in PTC. CXCL12 was validated as a direct target of miR-101 in PTC cells. More >

Yangjing Chen, Shaoqiang Zhang, Ruimin Zhao, Qian Zhao, Ting Zhang

Oncology Research, Vol.25, No.8, pp. 1215-1222, 2017, DOI:10.3727/096504016X14791715355957

Abstract Medullary thyroid carcinoma (MTC) is a neuroendocrine cancer derived from parafollicular C cells in the thyroid gland. It has great interest as a research focus because of its unusual genetic, clinical, and prognostic characteristics. However, the pathogenesis in MTC is not completely clear. We investigated the role of miR- 9-3p and bladder cancer-associated protein (BLCAP) in MTC TT cells. First, miR-9-3p expression was upregulated in human MTC tissues and TT cells and compared to the control by RT-PCR. Flow cytometric analysis indicated that the cell cycle progression in TT cells was significantly inhibited by the… More >

Fuqiang Wan^*, Li Peng^*, ChaoYu Zhu^†, XinFa Zhang^‡, FangWen Chen^*, Tao Liu^§

Oncology Research, Vol.25, No.4, pp. 503-510, 2017, DOI:10.3727/096504016X14755368915591

Abstract Latent transforming growth factor-b (TGF-b)-binding protein 2 (LTBP2) is one of four proteins in the LTBP family of proteins (LTBP1–4) and was shown to play a vital role in tumorigenesis. However, little is known regarding the functional role of LTBP2 in thyroid carcinoma. Therefore, the current study aimed to evaluate the effect of LTBP2 expression on the proliferation, invasion, and tumorigenesis in thyroid carcinoma cells and to explore the molecular mechanism of LTBP2 in tumor progression. Our results showed that the expression of LTBP2 is upregulated in human thyroid carcinoma and cell lines. Knockdown of More >

Anqi Yin^*†1, Chengguo Wang^‡1, Jiachen Sun^*1, Jianjun Gao^§, Liang Tao^†, Xilin Du^‡, Huadong Zhao^‡, Jiandong Yang^§, Yan Li^*†

Oncology Research, Vol.23, No.1-2, pp. 43-51, 2015, DOI:10.3727/096504015X14452563486093

Abstract Medullary thyroid carcinoma (MTC) is an uncommon and highly aggressive tumor of the neuroendocrine system, which derives from the neuroendocrine C cells of the thyroid gland. Except for surgical resection, there are not very many effective systemic treatment options for MTC. N-Myc downstream-regulated gene 2 (NDRG2) had a significantly lower expression in MTC compared with normal thyroid tissue. However, the function of NDRG2 in MTC oncogenesis is largely unknown. In this study, we found that overexpression of NDRG2 inhibited the proliferation of TT cells (human medullary thyroid carcinoma cells) in vitro and suppressed the development of MTC… More >